RON Receptor-Targeted Antibody-Drug Conjugate Therapy Ablates Cancer Stem Cells and Induces Long-term Tumor Regressions in Preclinical Models of Triple-Negative Breast Cancer (TNBC)

被引：0
|
作者：
Suthe, Sreedhar Reddy
Yao, Hang-Ping
Wang, Ming-Hai
机构：
来源：
FASEB JOURNAL | 2019年 / 33卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
510.3
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer
    Bardia, A.
    Spring, L. M.
    Juric, D.
    Partridge, A.
    Ligibel, J.
    Kuter, I.
    Peppercorn, J.
    Parsons, H.
    Ryan, P.
    Chawla, D.
    Attaya, V.
    Fitzgerald, D. M.
    Viscosi, E.
    Lormill, B.
    Shellock, M.
    Moy, B.
    Tolaney, S. M.
    Ellisen, L. W.
    ANNALS OF ONCOLOGY, 2020, 31 : S394 - S394
  • [42] Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer
    Modi, Shanu
    Pusztai, Lajos
    Forero, Andres
    Mita, Monica
    Miller, Kathy D.
    Weise, Amy
    Krop, Ian
    Burris, Howard, III
    Kalinsky, Kevin
    Tsai, Michaela
    Liu, Minetta C.
    Hurvitz, Sara A.
    Wilks, Sharon
    Ademuyiwa, Foluso
    Diab, Sami
    Han, Hyo S.
    Kato, Giraldo
    Nanda, Rita
    O'Shaughnessy, Joyce
    Kostic, Ana
    Li, Martha
    Specht, Jennifer
    CANCER RESEARCH, 2018, 78 (04)
  • [43] METRIC: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients (pts) with metastatic gpNMB-overexpressing triple-negative breast cancer (TNBC).
    Yardley, Denise A.
    Melisko, Michelle E.
    Forero, Andres
    Daniel, Brooke R.
    Montero, Alberto J.
    Guthrie, Troy H.
    Canfield, Vikki A.
    Oakman, Catherine Angela
    Chew, Helen K.
    Ferrario, Cristiano
    Volas-Redd, Gena H.
    Young, Robyn R.
    Henry, Norah Lynn
    Aneiro, Lynn
    He, Yi
    Turner, Christopher D.
    Davis, Thomas A.
    Vahdat, Linda T.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [44] Enhancing anti-tumor responses in triple-negative breast cancer by combining SIRP α inhibition with immunogenic chemotherapy or antibody-drug conjugates
    Ma, Xingru
    Tsao, Li-Chung
    Wang, Tao
    Liu, Cong-Xiao
    Gajda, Melissa
    Yang, Xiao
    Lei, Gangjun
    Wei, Junping
    Hartman, Zachary
    CANCER RESEARCH, 2024, 84 (06)
  • [45] Targeted epigenetic reprogramming reverts tumor progression in triple-negative breast cancer models by the activation of retinoic acid receptor alpha
    Bansal, Nidhi
    Bosch, Almudena
    Leibovitch, Boris A.
    Pierzchalski, Keely
    Zhou Ming-Ming
    Kane, Maureen
    Waxman, Samuel
    Farias, Eduardo
    CANCER RESEARCH, 2015, 75
  • [46] Development of a CUB domain-containing protein 1 (CDCP1)-targeting antibody-drug conjugate for triple-negative and metastatic breast cancer
    Gough, Madeline
    Kwah, Kayden
    He, Yaowu
    Snell, Cameron Edward
    Hooper, John D.
    Kryza, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial
    Bardia, A.
    Juric, D.
    Shimizu, T.
    Tolcher, A.
    Karim, R.
    Spira, A.
    Mukohara, T.
    Lisberg, A. E.
    Kogawa, T.
    Krop, I.
    Papadopoulos, K. P.
    Hamilton, E.
    Damodaran, S.
    Greenberg, J.
    Gu, W.
    Kobayashi, F.
    Guevara, F.
    Jikoh, T.
    Kawasaki, Y.
    Meric-Bernstam, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S60 - S60
  • [48] Preclinical Efficacy of Anti-RON Antibody Drug-Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase
    Yao, Hang-Ping
    Feng, Liang
    Weng, Tian-Hao
    Hu, Chen-Yu
    Suthe, Sreedhar Reddy
    Mostofa, A. G. M.
    Chen, Ling-Hui
    Wu, Zhi-Gang
    Wang, Wei-Lin
    Wang, Ming-Hai
    MOLECULAR PHARMACEUTICS, 2018, 15 (08) : 3260 - 3271
  • [49] AB-3A4: A novel KAAG1-targeting antibody-drug conjugate is active in models of ovarian carcinoma, triple-negative breast cancer and castration-resistant prostate cancer
    Tremblay, Gilles B.
    Moraitis, Anna
    Bedard, Dominique
    Orimoto, Adriana
    Page, Martine
    Mes-Masson, Anne-Marie
    Filion, Mario
    CANCER RESEARCH, 2014, 74 (19)
  • [50] BCG033, a novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, demonstrates preclinical efficacy against triple-negative breast cancer and other solid tumor xenografts
    Yao, Sufei
    Shang, Chengzhang
    An, Gao
    Guo, Chaoshe
    An, W. Frk
    Yang, Yi
    CANCER RESEARCH, 2024, 84 (06)
12345